Lance Willsey has bought stock on 2 days since May 2016

Insider Type: Person

Dr. Lance Willsey, M.S., M.D. is a physician and long‑tenured life sciences board member who has served as a Director at Exelixis, Inc. (Nasdaq: EXEL) for more than 25 years, including through the company’s growth as an oncology‑focused biotechnology firm.( As a corporate insider, he filed multiple Form 4 reports with the U.S. Securities and Exchange Commission in connection with his equity holdings and transactions in Exelixis stock.( In May 2023, Exelixis announced that Dr. Willsey had resigned from its Board of Directors, ending his service as an incumbent director during a period that included an activist proxy challenge.(

A urologist by training, Dr. Willsey has over three decades of combined experience on private and public company boards in cancer diagnostics and therapeutics, including prior directorships at Exact Sciences (1999–2009) and Exelixis (1997–2023), where he helped guide both companies through their initial public offerings and subsequent financings.( He is a founding partner of the healthcare investment fund DCF Capital, and has extensive corporate governance experience, having served on audit, compensation, finance, and scientific advisory committees.( Dr. Willsey completed his surgical and urology training at Massachusetts General Hospital, with additional postgraduate work in the Steele Laboratory at Harvard University and at the Dana‑Farber Cancer Institute, grounding his board and investment work in advanced clinical and research expertise.(

Written by Perplexity from public sources.